Malaria positivity following a single oral dose of azithromycin among children in Burkina Faso: a randomized controlled trial.

ABSTRACT:

Background

Azithromycin is a broad-spectrum antibiotic that has moderate antimalarial activity and has been shown to reduce all-cause mortality when biannually administered to children under five in high mortality settings in sub-Saharan Africa. One potential mechanism for this observed reduction in mortality is via a reduction in malaria transmission.

Methods

We evaluated whether a single oral dose of azithromycin reduces malaria positivity by rapid diagnostic test (RDT). We conducted an individually randomized placebo-controlled trial in Burkina Faso during the high malaria transmission season in August 2020. Children aged 8 days to 59 months old were randomized to a single oral dose of azithromycin (20 mg/kg) or matching placebo. At baseline and 14 days following treatmen

SUBMITTER: Brogdon J 

PROVIDER: S-EPMC8957146 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature